WO2023242810 - MCHR1 ANTAGONISTS FOR THE TREATMENT OF PRADER-WILLI SYNDROME
National phase entry is expected:
Publication Number
WO/2023/242810
Publication Date
21.12.2023
International Application No.
PCT/IB2023/056245
International Filing Date
16.06.2023
Title **
[English]
MCHR1 ANTAGONISTS FOR THE TREATMENT OF PRADER-WILLI SYNDROME
[French]
ANTAGONISTES DE MCHR1 POUR LE TRAITEMENT DU SYNDROME DE PRADER-WILLI
Applicants **
RICHTER GEDEON NYRT.
Inventors
OLÁH, Márk
BOROS, András
Priority Data
P2200222
17.06.2022
HU
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2620 | |
| EPO | Filing, Examination, Granting | 18334 | |
| Japan | Filing, Examination, Granting | 2770 | |
| South Korea | Filing, Examination, Granting | 3319 | |
| USA | Filing, Examination, Granting | 14340 |
Total:
41,383
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to uses of a melanin-concentrating hormone receptor 1 (MCHR1) antagonist, e.g., a compound of formula (I), or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions thereof for the treatment of Prader-Willi Syndrome, for improving, alleviating or delaying progression of one or more symptoms of Prader-Willi Syndrome, such as hyperphagia, for maintaining or reducing body weight, or for reducing food intake in a patient afflicted with Prader-Willi Syndrome.[French]
La présente invention concerne des utilisations d'un antagoniste du récepteur 1 de l'hormone concentrant la mélanine (MCHR1), tel que, par exemple, un composé de formule (I), ou un sel pharmaceutiquement acceptable de celui-ci, ou des compositions pharmaceutiques de celui-ci pour le traitement du syndrome de Prader-Willi, pour améliorer, atténuer ou retarder un ou plusieurs symptômes du syndrome de Prader-Willi, tels que l'hyperphagie, pour maintenir ou réduire le poids corporel, ou pour réduire la prise alimentaire chez un patient atteint du syndrome de Prader-Willi.